Real-world data (RWD) and Artificial Intelligence (AI) are evolving fast, and with the integration of unstructured data, large language models (LLMs), and multimodal data sources, the next generation of RWD
In October 2025, Norstella brought together key leaders in the pharmaceutical space and Norstella’s top RWD/AI experts for a day of discussion on how real-world data (RWD) and AI are
Innovation at Norstella often begins with a question: What if we could move faster—without sacrificing quality or compliance? During a recent hackathon, Norstella’s commercial and product teams had a chance
As clinical trials increase in number and complexity, so does the competition for the patients best aligned to the study requirements. And with clinical trial processes relatively unchanged over the
Real-world data (RWD) is transforming the life sciences industry, giving pharma companies valuable insights into the patient journey and helping more people get the life-saving treatments they need. To discuss
Dan Chancellor, VP, Thought Leadership, Lance Wolkenbrod, Senior Principal, RWD Solutions, and Dr. Madeline Naylor, Chief Clinician, at Norstella discuss
In episode two of Real-World Data After Dark, Lance Wolkenbrod, Senior Principal, RWD Solutions, and Dr. Madeline Naylor, Chief Clinician,
Dan Chancellor, VP, Thought Leadership at Norstella, introduces Norstella’s real-world data experts, Dr. Madeline Naylor, Chief Clinician, and Lance Wolkenbrod,
Pharma leaders agree that real-world data (RWD) is essential—but many still struggle to harness its full potential. In Real-World Data
Real-world data has already proven its power to transform patient outcomes, accelerate clinical development, and strengthen commercial strategies, but its
From clinical trials to regulatory submissions to HEOR research, the value of real-world data (RWD) is clear. So how are